8-K filed Nov 2, 2026 at 16:04 ET
Tactile Medical reported Q3 2026 revenue of $91.9M (+7% YoY), slightly below the $92.0M consensus, and GAAP EPS of $0.31, below the $0.34 consensus. Net income declined to $7.2M from $8.2M a year ago, and Adjusted EBITDA was essentially flat at $14.3M. The company maintained its full-year revenue guidance of $360M-$366M but raised its Adjusted EBITDA guidance to $50M-$52M from $49M-$51M. The core lymphedema business grew 13% YoY, but airway clearance revenue fell 25% due to DME inventory transition, and operating expenses rose 13%.